Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

VolitionRx Extends Agreement with University Hospital Bonn to Include CE Mark Performance Evaluation

Published: Thursday, April 24, 2014
Last Updated: Thursday, April 24, 2014
Bookmark and Share
The agreement also doubles the Hospital’s prospective trial of 20 cancers, and adds a range of additional vital background work.

volition_pipetting_resized.gifVolitionRx has extended its agreement with University Hospital Bonn, Germany, pursuant to which University Hospital Bonn will externally conduct the performance evaluation for CE marking of VolitionRx’s proprietary NuQ® assays as a tool for detecting colorectal cancer. Additionally, as part of the agreement, the Hospital has doubled the size of its prospective study from 2,000 to 4,000 patients and agreed to a range of other work including launching a 100-patient lung cancer-specific prognostic monitoring trial.

The CE mark performance evaluation will be led by Priv-Doz. Dr. Stefan Holdenrieder at the Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn. His team will use VolitionRx’s NuQ® kits as a confirmatory trial on patient samples from VolitionRx’s ongoing collaboration with Hvidovre Hospital, Denmark, for CE regulatory purposes.  Dr. Holdenrieder is also leading the expanded German prospective study, which is designed to evaluate the performance of VolitionRx’s assays across patients with the 20 most prevalent cancer types and matched healthy individuals and those with competing conditions. 

Dr. Holdenrieder commented, “VolitionRx has seen some impressive results in recent months, with significant differentiation shown. If the data continues to impress, we believe this technology could have great potential and we want to be at the heart of this research. With that said, we decided to expand our prospective trial and agreed to run the performance evaluation for colorectal cancer.  We hope our research further confirms the accuracy of these tests and allows their clinical use in Europe.”

NuQ-Kit_resized.gifCameron Reynolds, CEO of VolitionRx, added, “We’d like to thank Dr. Stefan Holdenrieder’s team for their continued support, and we are excited to expand our collaboration. University Hospital Bonn’s performance evaluation will be crucial to our CE mark application process, which we aim to complete in 2014. Also, the doubling of their prospective multi-cancer trial will give us a very good indication of the nucleosome structures in a very wide range of cancers.”

As part of the expanded collaboration, University Hospital Bonn will also perform a wide range of beta testing and pre analytics that are key to further refining the Nucleosomics technology.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

VolitionRx Invests in Laboratory Automation System
Automation will accelerate analysis of blood samples for expanded colorectal cancer screening trial.
Wednesday, August 13, 2014
VolitionRx’s NuQ® Assays Demonstrate 80% Detection Rate in Prostate Cancer
Study data also demonstrates ability to distinguish between prostate and colorectal cancer.
Monday, March 17, 2014
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Searching Big Data Faster
Theoretical analysis could expand applications of accelerated searching in biology, other fields.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Reprogramming Cancer Cells
Researchers on Mayo Clinic’s Florida campus have discovered a way to potentially reprogram cancer cells back to normalcy.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
How DNA ‘Proofreader’ Proteins Pick and Edit Their Reading Material
Researchers from North Carolina State University and the University of North Carolina at Chapel Hill have discovered how two important proofreader proteins know where to look for errors during DNA replication and how they work together to signal the body’s repair mechanism.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!